GENE Solutions Phils.

12/10/2026

October is Breast Cancer Awareness Month!

Spot early signals of 5-10(*) common and aggressive cancers, like BREAST Cancer, using next generation of ctDNA technology.

Ask you Doctor about Spot-Mas 10 Mulit-cancer Early Detection Test.

https://genesolutions.com/our-test/spot-mas

GENE Solutions Phils.

06/10/2026

Excited for ESMO 2026!

28/09/2026

Every cancer is different. Your care is personal. Your testing can be too.
Even people with the same type of cancer may respond differently to treatment because each tumor can have molecular biomarker profile.
Biomarker testing may help doctors identify treatment options matched to your cancer. ctDNA testing uses a blood sample to monitor cancer-related changes and assess treatment response over time.
Gene Solutions offers two complementary solutions:
🔹 K-4CARE: Comprehensive DNA and RNA profiling, combined with highly sensitive personalized ctDNA monitoring.
🔹 K-TRACK: Focused genomic profiling, combined with sensitive personalized ctDNA monitoring.
Together, K-4CARE and K-TRACK provide connected insights throughout the cancer care journey, from exploring treatment options to monitoring changes over time.
👉 Explore our solutions: https://rebrand.ly/oncoPT_Fly
📖 Read the full article here: https://rebrand.ly/GScancercare
💬 Ask your doctor whether biomarker and ctDNA testing may be appropriate for you.

🧬 Every cancer is different. Your care is personal. Your testing can be too.

Even people with the same type of cancer may respond differently to treatment because each tumor can have molecular biomarker profile.

Biomarker testing may help doctors identify treatment options matched to your cancer. ctDNA testing uses a blood sample to monitor cancer-related changes and assess treatment response over time.

Gene Solutions offers two complementary solutions:

🔹 K-4CARE: Comprehensive DNA and RNA profiling, combined with highly sensitive personalized ctDNA monitoring.
🔹 K-TRACK: Focused genomic profiling, combined with sensitive personalized ctDNA monitoring.

Together, K-4CARE and K-TRACK provide connected insights throughout the cancer care journey, from exploring treatment options to monitoring changes over time.

👉 Explore our solutions: https://rebrand.ly/oncoPT_Fly
📖 Read the full article here: https://rebrand.ly/GScancercare
💬 Ask your doctor whether biomarker and ctDNA testing may be appropriate for you.

22/09/2026

Multi-omic liquid biopsy will reshape clinical practice only when it moves from technological innovation to evidence-based decisions that health systems can implement at scale.
This is the focus of the ESMO 2026 Industry Satellite Symposium hosted by Gene Solutions:
AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

Gene Solutions at the ESMO 2026!

08/09/2026

27/08/2026

Cancer is often silent in its early stages. Detection shouldn't be.
Catching cancer early can make a critical difference in treatment options and patient outcomes.
Discover SPOT-MAS 10: an advanced, AI-powered blood test designed to detect circulating tumor DNA signals across multiple cancer types.
Clinically validated with an overall 78.1% sensitivity and 99.8% specificity, SPOT-MAS 10 has been granted U.S. FDA Breakthrough Device Designation (BDD)*, recognizing its potential to transform multi-cancer detection.
Learn more: https://genesolutions.com/our-test/spot-mas
*Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. SPOT-MAS 10 remains subject to future FDA review.

10/08/2026

Can molecular precision help reduce unnecessary invasive procedures for women at risk of endometrial cancer?...

Can molecular precision help reduce unnecessary invasive procedures for women at risk of endometrial cancer?

On the final day of ISPD 2026, Gene Solutions' scientific session showcased how DNA methylation technology may support a more patient-friendly approach to endometrial cancer screening and triage.

👉Read the full announcement: https://genesolutions.com/news/gene-solutions-showcases-global-evidence-and-responsible-innovation-in-prenatal-and-womens-genomic-health-at-ispd-2026

The session brought together international experts to discuss epiHERA®, a cervical-sample DNA methylation assay designed to help triage women with abnormal uterine bleeding or an elevated risk of endometrial cancer.
Highlights included:
🔹 Clinical evidence supporting methylation biomarkers as a less-invasive triage tool before endometrial biopsy or dilation and curettage (D&C).
🔹 US validation data demonstrating 90.2% sensitivity and 96.2% specificity. The assay uses familiar liquid-based cervical cytology workflows, supporting its potential integration into existing clinical practice.
🔹 Expert perspectives on addressing current diagnostic challenges by improving specificity, identifying patients who require further investigation, and potentially reducing unnecessary invasive procedures.

The session featured presentations by Dr. Lee Ho Sze Jacqueline, Honorary Clinical Associate Professor at The Chinese University of Hong Kong, and Dr. Safedin Sajo Beqaj of Gnosis Laboratories, California, US.

The discussion reflected Gene Solutions' commitment to advancing evidence-based, minimally invasive molecular diagnostics that improve women's healthcare through responsible innovation and global collaboration.

👉Learn more about the integrated gynecological test​: https://spotmas.com/eva/

03/08/2026

From Asia-led evidence to global recognition.
2026 has been a landmark year for SPOT-MAS, with real-world data from six Asian countries highlighted at ASCO and the test receiving U.S. FDA Breakthrough Device Designation*.